NCT06744920: An ongoing trial by Novartis Pharmaceuticals
This trial is ongoing. It must report results 3 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06744920 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 7, 2025 |
| Completion date | Feb. 27, 2028 |
| Required reporting date | Feb. 26, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |